Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result Spotlight
Head and neck cancer
Sequential Pembrolizumab (PD-1) Tops Concurrent for 4-yr Control in LA-HNSCC
Pembrolizumab—an anti-PD-1 antibody—was tested with definitive chemoradiation (CRT: weekly cisplatin 40 mg/m² + 70 Gy RT) either concurrently (start 1 wk pre-CRT) or sequentially (start 2 wks post-CRT) in a…
NCT02777385 - Trial result
Head and neck cancer
ECOG-ACRIN E3311: TOS + Reduced-Dose RT Yields 54-mo PFS 90.6% in HPV+ Oropharyngeal Cancer
ECOG-ACRIN E3311 (phase II; NCT01898494) tested transoral surgery (TOS) with risk-based adjuvant management—observation for low-risk (arm A), IMRT 50 (arm B) vs 60 Gy (arm C) for intermediate-risk, or weekly…
NCT01898494 - Trial result Spotlight
Melanoma
FMT + Anti-PD-1 Delivers 65% ORR and mPFS 29.6 mo in Frontline Melanoma
The MIMic phase I trial (multicenter; NCT03772899) gave a single oral fecal-microbiota transplant (healthy-donor stool) followed by standard anti-PD-1 as first-line therapy for advanced melanoma (n=20). ORR was 65%…
NCT03772899 - Trial result
Non-small cell lung cancer
Sotorasib (KRAS G12C) Improves CNS PFS vs Docetaxel in Pretreated NSCLC
CodeBreaK 200 (phase 3; global; NCT04303780) randomized previously treated KRAS G12C-mutated advanced NSCLC (~10–13% of non-squamous NSCLC) to Amgen's sotorasib 960 mg daily vs docetaxel 75 mg/m² q3w; this…
NCT04303780 - Trial result
Non-small cell lung cancer
BL-B01D1 (EGFR×HER3 ADC) cORR 54–67% in Exon20/HER2-Mutant NSCLC
Iza-bren (BL-B01D1) is an EGFR×HER3 bispecific ADC carrying a topo-I payload (Ed-04) via a tetrapeptide cleavable linker; in a phase Ib expansion (NCT05194982), adults with advanced NSCLC harboring pre-specified…
NCT05194982 - Trial result
Lymphoma
Acalabrutinib+Lenalidomide+Rituximab (BTK+IMiD+CD20) Hits 92% CR in Frontline High-Burden FL
Acalabrutinib (BTK inhibitor) plus lenalidomide (IMiD) and rituximab (anti-CD20) was tested first-line in a single-arm phase II for advanced-stage follicular lymphoma with high tumor burden (n=24; NCT04404088; median…
NCT04404088 - Trial result
Lymphoma
Obinutuzumab (CD20) Induction+Maintenance Delivers 65% ORR in Relapsed Waldenström’s
Single-arm phase II (NCT03679455) tested obinutuzumab 1000 mg monotherapy (induction then q8wk maintenance ×2 yrs) in relapsed/refractory Waldenström macroglobulinaemia (n=23; median follow-up 3.8 yrs). Best overall…
NCT03679455 - Trial result
Lymphoma
NKTR-255 (IL-15R agonist) Lifts 6-mo CR After CD19 CAR-T in R/R LBCL
Phase 2, randomized, double-blind, placebo-controlled multicenter study (NCT05664217) tested NKTR-255—an IL-15 receptor agonist designed to expand CD8 T and NK cells—given after axi-cel or liso-cel in…
NCT05664217 - New trial Spotlight
Breast cancer
Phase II STEMVAC DNA Vaccine Targeting Breast Cancer Stem Cell Proteins
This phase II trial investigates STEMVAC in combination with standard endocrine therapy plus a CDK4/6 inhibitor or capecitabine in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.…
NCT07112053 Exploratory - New trial
Breast cancer
Phase 3 trial: RLY-2608, a PI3K alpha inhibitor, with fulvestrant for advanced HR+/HER2– breast cancer
This global, multicenter open-label randomized study compares RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant in patients with locally advanced or metastatic HR+/HER2– breast cancer harboring PIK3CA…
NCT06982521 Registrational - New trial
Chronic lymphocytic leukemia
Phase 2 trial: Epcoritamab, CD20/CD3 bispecific antibody
This Phase 2 study evaluates Epcoritamab, a bispecific antibody that binds CD20 and CD3, as consolidation therapy in patients with CLL/SLL or variants following 2nd-line treatment with a 2nd generation BTKi.…
NCT07108998 Exploratory - New trial
Liver and bile duct cancer
Phase 2 trial of TheraSphere Yttrium-90 microspheres for liver internal radiation therapy
This prospective, single-arm, open-label Phase 2 trial at the University of California, San Francisco evaluates trans-arterial radiation segmentectomy for patients with unresectable hepatocellular carcinoma (BCLC…
NCT07110233 Exploratory - New trial Spotlight
Prostate cancer
Phase 2 Tarlatamab Study: DLL3/CD3 bispecific antibody in metastatic prostate cancer.
This Phase 2 trial evaluates tarlatamab, a DLL3 and CD3 directed bispecific monoclonal antibody, in patients with metastatic, DLL3‐positive prostate cancer that is refractory or relapsed after prior treatment (where…
NCT07111507 Exploratory - New trial
Multiple myeloma
Phase 1b teclistamab (BCMA/CD3 bispecific antibody) and mezigdomide (cereblon modulator) for relapsed/refractory multiple myeloma.
This Phase 1b study led by Memorial Sloan Kettering is evaluating the safety and effectiveness of combining teclistamab and mezigdomide in patients with relapsed/refractory multiple myeloma who have received at least…
NCT07105059 Exploratory - New trial Spotlight
Bladder and urothelial cancer
Phase 2/3 Izalontamab Brengitecan EGFR/HER3 bispecific ADC in metastatic urothelial cancer
This study, sponsored by Bristol-Myers Squibb and conducted at multiple international sites, is evaluating a novel ADC targeting EGFR/HER3 (BMS-986507) against standard platinum-based chemotherapy (cisplatin,…
NCT07106762 Registrational - New trial
Liver and bile duct cancer
Phase I trial of CA-4948 IRAK4/FLT3 inhibitor combined with chemoimmunotherapy in advanced biliary cancer
This trial evaluates CA-4948, an IRAK4/FLT3 inhibitor, with gemcitabine (ribonucleotide reductase inhibitor), cisplatin (DNA synthesis inhibitor), and durvalumab (PD-L1 antibody) on a 21-day cycle in treatment-naïve…
NCT07107750 Exploratory - New trial
Multiple solid tumors
Phase Ia/b study of DSB2455, a PARP1 inhibitor in advanced malignancies
This Phase Ia/b open-label adaptive trial evaluates the safety, tolerability, and activity of DSB2455, a small molecule PARP1 selective inhibitor, as monotherapy in participants with advanced or metastatic breast,…
NCT06458712 First-in-human - Trial result Spotlight
Brain and CNS tumors
DOC1021 Autologous DC Vaccine Hits 88% 12-mo OS in IDH-wt GBM (Phase I)
DOC1021 is an autologous dendritic-cell vaccine loaded with each patient’s tumor lysate plus amplified tumor mRNA and injected near deep cervical nodes with weekly peg-IFN after chemoradiation. In a single-arm…
NCT04552886 - Trial result Spotlight
Uterine (endometrial) cancer
PARP Inhibitor Rucaparib Extends PFS to 28 mo in Metastatic/Recurrent Endometrial Cancer
Rucaparib, an oral PARP1/2 inhibitor that exploits tumor DNA-repair defects, was tested as switch-maintenance after 1–2 chemotherapy lines in a double-blind Phase II trial (NCT03617679). Seventy-nine patients with…
NCT03617679 - Trial result Spotlight
Non-small cell lung cancer
Pralsetinib (Selective RET TKI): ctDNA Clearance Flags 12-mo + PFS in RET-Fusion NSCLC
Pralsetinib, an oral CNS-penetrant RET tyrosine-kinase inhibitor, was evaluated in a single-arm prospective biomarker study of 21 Chinese patients with advanced RET-fusion NSCLC (Phase 2 ARROW, NCT03037385). Baseline…
NCT03037385 - Trial result
Non-small cell lung cancer
Consolidative SRT After 1L Chemo-IO Yields 29-mo mPFS in Oligo-Residual NSCLC (Phase 2)
Stereotactic radiotherapy (SRT) to all oligo-residual lesions was delivered while continuing maintenance systemic therapy after effective first-line chemo-immunotherapy in a single-arm study from China (driver…
NCT04767009 - Trial result
Lung cancer
ctDNA Tumor Fraction Clearance Predicts Longer rwPFS/OS in NSCLC & SCLC
A tissue-agnostic ctDNA tumor-fraction (TF) assay measured 6–15 weeks after therapy start (prospective clinico-genomic registry; NCT04180176) associated undetectable TF with longer real-world outcomes: NSCLC mPFS…
NCT04180176 - Trial result Spotlight
Myeloproliferative neoplasms
Avapritinib (KIT D816V) Beats Midostaurin/Cladribine on OS in AdvSM
Avapritinib, a selective KIT D816V inhibitor, was compared via IPTW-adjusted external controls to midostaurin (multikinase/KIT) or cladribine (purine analog) using EXPLORER/PATHFINDER trial patients (n=176) versus…
- Trial result
Lymphoma
Evorpacept (CD47) + Lenalidomide/Rituximab Achieves 80% CR in R/R B-NHL (Phase I)
Evorpacept (ALX148) is a high-affinity CD47 blocker with an inactive Fc to promote macrophage phagocytosis while limiting cytopenias; added to lenalidomide and rituximab (R2) in a single-arm Phase I (n=20; ≥2 prior…
NCT05025800 - Trial result
Colorectal cancer
Panitumumab (EGFR) Maintenance: Spatial Immune Markers Predict Benefit in RAS-WT mCRC
Panitumumab, an anti-EGFR IgG2, was tested as FU/FA maintenance (±Pmab) after Pmab+FOLFOX induction in PanaMa; this translational analysis profiled 12 immune markers in tumor/stroma compartments from resections…
NCT01991873 - Trial result
Other cancers
Selinexor (XPO1) Yields 13.6-mo mPFS in Thymoma, 7.8-mo in Thymic Carcinoma (Phase II)
Selinexor, an oral exportin-1 (XPO1/CRM1) inhibitor, was tested in two coordinated single-arm Phase II trials (US/EU) in pretreated advanced thymic epithelial tumors (n=31; median 2 prior lines). Dosed twice weekly…
- Trial result Spotlight
Bladder and urothelial cancer
TAR-200 Intravesical Gemcitabine Device Posts 82% CR in BCG-Unresponsive CIS (Phase IIb)
TAR-200 is an osmotic intravesical drug-releasing system for sustained gemcitabine delivery; in SunRISe-1, BCG-unresponsive high-risk NMIBC received TAR-200 alone, TAR-200+cetrelimab (PD-1), or cetrelimab alone…
- New trial
Breast cancer
Phase II STEMVAC DNA vaccine targeting breast cancer stem cell antigens.
This Phase II trial at University of Washington evaluates the immunogenicity of STEMVAC, a DNA vaccine engineered to stimulate Th1 responses against MDM2, YB1, SOX2, CDH3, and CD105 expressed by breast cancer stem…
NCT07078604 Exploratory - New trial
Breast cancer
Phase II Hypofractionated EBRT, fine-tuning targeted ionizing radiation for nodal control in breast cancer.
This Phase II trial at M.D. Anderson evaluates shortened adjuvant regional nodal irradiation schedules using hypofractionated external beam radiation therapy (EBRT) via different dose regimens, including simultaneous…
NCT07076485 Exploratory - New trial Spotlight
Prostate cancer
Phase 1b pTVG-HP DNA vaccine and sasanlimab PD-1 inhibitor in oligometastatic prostate cancer
This study evaluates the combination of an investigational pTVG-HP DNA vaccine (targeting prostatic acid phosphatase) and sasanlimab, a PD-1 blocking monoclonal antibody, with radiation therapy in non-castrate,…
NCT07090148 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.